ORGO Stock Overview
Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 3/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Organogenesis Holdings Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.39 |
| 52 Week High | US$4.71 |
| 52 Week Low | US$1.96 |
| Beta | 1.57 |
| 1 Month Change | -15.55% |
| 3 Month Change | -30.32% |
| 1 Year Change | 11.16% |
| 3 Year Change | -87.61% |
| 5 Year Change | -65.81% |
| Change since IPO | -82.22% |
Recent News & Updates
Shareholders Should Be Pleased With Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Price
May 01
Is Organogenesis Holdings (NASDAQ:ORGO) Using Too Much Debt?
Apr 10Recent updates
Shareholders Should Be Pleased With Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Price
May 01Is Organogenesis Holdings (NASDAQ:ORGO) Using Too Much Debt?
Apr 10These 4 Measures Indicate That Organogenesis Holdings (NASDAQ:ORGO) Is Using Debt Reasonably Well
Jan 04Is Organogenesis Holdings (NASDAQ:ORGO) Using Too Much Debt?
May 31Does Organogenesis Holdings (NASDAQ:ORGO) Have A Healthy Balance Sheet?
Jan 19Organogenesis: Finding A Spot For This Regenerative Medicines Company In My 'Bio Boom' Portfolio
Oct 18Here's Why Organogenesis Holdings (NASDAQ:ORGO) Can Manage Its Debt Responsibly
Sep 23Organogenesis gets FDA clearance for PuraPly MZ for wound healing
Aug 15Here's Why Organogenesis Holdings (NASDAQ:ORGO) Has Caught The Eye Of Investors
Jul 28Here's Why Organogenesis Holdings (NASDAQ:ORGO) Can Manage Its Debt Responsibly
Jun 10Organogenesis Holdings: What Now
May 18The Market Doesn't Like What It Sees From Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Earnings Yet
Mar 31These 4 Measures Indicate That Organogenesis Holdings (NASDAQ:ORGO) Is Using Debt Reasonably Well
Mar 04Organogenesis Holdings (NASDAQ:ORGO) Seems To Use Debt Quite Sensibly
Nov 30Organogenesis Holdings Inc. (NASDAQ:ORGO) Shares Could Be 24% Above Their Intrinsic Value Estimate
Sep 27These 4 Measures Indicate That Organogenesis Holdings (NASDAQ:ORGO) Is Using Debt Reasonably Well
Jul 15Shareholder Returns
| ORGO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -2.6% | 3.4% | 1.6% |
| 1Y | 11.2% | 3.8% | 25.1% |
Return vs Industry: ORGO exceeded the US Biotechs industry which returned 2.8% over the past year.
Return vs Market: ORGO underperformed the US Market which returned 23.9% over the past year.
Price Volatility
| ORGO volatility | |
|---|---|
| ORGO Average Weekly Movement | 11.4% |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ORGO's share price has been volatile over the past 3 months.
Volatility Over Time: ORGO's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1985 | 862 | Gary Gillheeney | organogenesis.com |
Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company’s advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage. Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; PuraPly MZ, a micronized particulate version of PuraPly for the management of open wounds in the surgical setting; and CYGNUS Dual, a dehydrated placental tissue preserved to retain the ECM scaffold.
Organogenesis Holdings Inc. Fundamentals Summary
| ORGO fundamental statistics | |
|---|---|
| Market cap | US$316.85m |
| Earnings (TTM) | US$4.95m |
| Revenue (TTM) | US$433.14m |
64.1x
P/E Ratio0.7x
P/S RatioIs ORGO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ORGO income statement (TTM) | |
|---|---|
| Revenue | US$433.14m |
| Cost of Revenue | US$106.48m |
| Gross Profit | US$326.66m |
| Other Expenses | US$321.71m |
| Earnings | US$4.95m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 09, 2024
| Earnings per share (EPS) | 0.037 |
| Gross Margin | 75.42% |
| Net Profit Margin | 1.14% |
| Debt/Equity Ratio | 23.8% |
How did ORGO perform over the long term?
See historical performance and comparison